JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $125 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a $125 price target.
June 07, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Blueprint Medicines and maintained a $125 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $125 by JMP Securities suggests strong confidence in Blueprint Medicines' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100